Literature DB >> 28465374

Regulation of δ Opioid Receptor-Mediated Signaling and Antinociception in Peripheral Sensory Neurons by Arachidonic Acid-Dependent 12/15-Lipoxygenase Metabolites.

Laura C Sullivan1, Teresa A Chavera1, Xiaoli Gao1, Miryam M Pando1, Kelly A Berg2.   

Abstract

The function of δ opioid receptors (DOR) expressed by peripheral pain-sensing neurons (nociceptors) is regulated by both cyclooxygenase- and lipoxygenase (LOX)-dependent arachidonic acid (AA) metabolites. Whereas cyclooxygenase metabolites enhance responsiveness, LOX metabolites elicit a refractory, nonsignaling state of the DOR receptor system for antinociceptive signaling. In this study, using high-performance liquid chromatography-tandem mass spectrometry analyses, we have found that the 12-/15-LOX metabolites, 12-hydroxyeicosatetraenoic acid (HETE) and 15-HETE, were elevated after treatment of adult rat primary sensory neuron cultures with AA. Exogenously applied 12-HETE and 15-HETE, but not 5-HETE, completely prevented DOR and κ opioid receptor (KOR) agonist-mediated inhibition of prostaglandin E2 (PGE2)-stimulated cAMP accumulation, but not inhibition, by the 5-HT1 receptor agonist 5-carboxamidotryptamine in cultured peripheral sensory neurons and in Chinese hamster ovary (CHO) cells heterologously expressing DOR or KOR. Similarly, intraplantar injection of 12- or 15-HETE, either alone or in combination, prevented DOR agonist-mediated inhibition of PGE2-evoked thermal allodynia. Further, both AA- and carrageenan-mediated induction of the nonresponsive state of the DOR system was blocked by an intraplantar coinjection of the 12-/15-LOX inhibitors baicalein and luteolin. In contrast to the regulation of cAMP signaling, pretreatment with 12- and 15-HETE had no effect on either DOR or KOR agonist- mediated activation of extracellular signal-regulated kinase in peripheral sensory neurons or CHO cells. These results suggest that the analgesic efficacy of peripherally restricted opioids for treatment of inflammatory pain may be enhanced by adjunct inhibition of LOX activity.
Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28465374      PMCID: PMC6040089          DOI: 10.1124/jpet.117.241604

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  30 in total

1.  Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances.

Authors:  S W Hwang; H Cho; J Kwak; S Y Lee; C J Kang; J Jung; S Cho; K H Min; Y G Suh; D Kim; U Oh
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

2.  Inhibition of 15-lipoxygenases by flavonoids: structure-activity relations and mode of action.

Authors:  Christian David Sadik; Helmut Sies; Tankred Schewe
Journal:  Biochem Pharmacol       Date:  2003-03-01       Impact factor: 5.858

3.  Baicalein and 12/15-lipoxygenase in the ischemic brain.

Authors:  Klaus van Leyen; Hahn Young Kim; Seong-Ryong Lee; Guang Jin; Ken Arai; Eng H Lo
Journal:  Stroke       Date:  2006-10-19       Impact factor: 7.914

4.  Baicalein is a potent in vitro inhibitor against both reticulocyte 15-human and platelet 12-human lipoxygenases.

Authors:  Joshua D Deschamps; Victor A Kenyon; Theodore R Holman
Journal:  Bioorg Med Chem       Date:  2006-02-24       Impact factor: 3.641

5.  PAR-2 agonists activate trigeminal nociceptors and induce functional competence in the delta opioid receptor.

Authors:  Amol M Patwardhan; Anibal Diogenes; Kelly A Berg; Jill C Fehrenbacher; William P Clarke; Armen N Akopian; Kenneth M Hargreaves
Journal:  Pain       Date:  2006-06-14       Impact factor: 6.961

6.  Bradykinin-induced functional competence and trafficking of the delta-opioid receptor in trigeminal nociceptors.

Authors:  Amol M Patwardhan; Kelly A Berg; Armen N Akopain; Nathaniel A Jeske; Nikita Gamper; William P Clarke; Kenneth M Hargreaves
Journal:  J Neurosci       Date:  2005-09-28       Impact factor: 6.167

7.  Integrins regulate opioid receptor signaling in trigeminal ganglion neurons.

Authors:  K A Berg; G Zardeneta; K M Hargreaves; W P Clarke; S B Milam
Journal:  Neuroscience       Date:  2006-12-08       Impact factor: 3.590

8.  The narcotic bowel syndrome: clinical features, pathophysiology, and management.

Authors:  David M S Grunkemeier; Joseph E Cassara; Christine B Dalton; Douglas A Drossman
Journal:  Clin Gastroenterol Hepatol       Date:  2007-10       Impact factor: 11.382

9.  Peripheral delta opioid receptors require priming for functional competence in vivo.

Authors:  Matthew P Rowan; Nikita B Ruparel; Amol M Patwardhan; Kelly A Berg; William P Clarke; Kenneth M Hargreaves
Journal:  Eur J Pharmacol       Date:  2008-11-25       Impact factor: 4.432

10.  Rapid modulation of micro-opioid receptor signaling in primary sensory neurons.

Authors:  Kelly A Berg; Amol M Patwardhan; Teresa A Sanchez; Yamille M Silva; Kenneth M Hargreaves; William P Clarke
Journal:  J Pharmacol Exp Ther       Date:  2007-03-08       Impact factor: 4.030

View more
  4 in total

1.  Signaling characteristics and functional regulation of delta opioid-kappa opioid receptor (DOP-KOP) heteromers in peripheral sensory neurons.

Authors:  Blaine A Jacobs; Miryam M Pando; Elaine M Jennings; Raehannah J Jamshidi; Joshua C Zamora; Teresa S Chavera; William P Clarke; Kelly A Berg
Journal:  Neuropharmacology       Date:  2019-02-15       Impact factor: 5.250

2.  Screening drug target combinations in disease-related molecular networks.

Authors:  Min Luo; Jianfeng Jiao; Ruiqi Wang
Journal:  BMC Bioinformatics       Date:  2019-05-01       Impact factor: 3.169

3.  Long-term antagonism and allosteric regulation of mu opioid receptors by the novel ligand, methocinnamox.

Authors:  Joshua C Zamora; Hudson R Smith; Elaine M Jennings; Teresa S Chavera; Varun Kotipalli; Aleasha Jay; Stephen M Husbands; Alex Disney; Kelly A Berg; William P Clarke
Journal:  Pharmacol Res Perspect       Date:  2021-12

Review 4.  Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity.

Authors:  Kelly A Berg; William P Clarke
Journal:  Int J Neuropsychopharmacol       Date:  2018-10-01       Impact factor: 5.176

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.